| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4795494
Max Phase: Preclinical
Molecular Formula: C19H15NO3
Molecular Weight: 305.33
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: CC(=O)c1ccc(Nc2cccc(C(=O)O)c2)c2ccccc12
Standard InChI: InChI=1S/C19H15NO3/c1-12(21)15-9-10-18(17-8-3-2-7-16(15)17)20-14-6-4-5-13(11-14)19(22)23/h2-11,20H,1H3,(H,22,23)
Standard InChI Key: WTVWFZNHZAQDRY-UHFFFAOYSA-N
Associated Targets(Human)
Aldo-keto reductase family 1 member C4 224 Activities
Aldo-keto reductase family 1 member C2 639 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Aldo-keto-reductase family 1 member C3 1414 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Aldo-keto reductase family 1 member C1 475 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 305.33 | Molecular Weight (Monoisotopic): 305.1052 | AlogP: 4.48 | #Rotatable Bonds: 4 |
| Polar Surface Area: 66.40 | Molecular Species: ACID | HBA: 3 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 4.75 | CX Basic pKa: | CX LogP: 3.62 | CX LogD: 1.02 |
| Aromatic Rings: 3 | Heavy Atoms: 23 | QED Weighted: 0.70 | Np Likeness Score: -0.66 |
References
| 1. Liu Y,He S,Chen Y,Liu Y,Feng F,Liu W,Guo Q,Zhao L,Sun H. (2020) Overview of AKR1C3: Inhibitor Achievements and Disease Insights., 63 (20.0): [PMID:32463235] [10.1021/acs.jmedchem.9b02138] |
Source
Source(1):